Modulation of postoperative scarring with tacrolimus and octreotide in experimental glaucoma filtration surgery

Current Eye Research

Volumn 37, Issue 3, 2012, Pages 228-233

  Arslan, Sermal ^a   Aydemir, Orhan ^a   Gler, Mete ^b   Daǧli, Adile Ferda ^a  

^a FIRAT UNIVERSITY   (Turkey)

^b Elazi Harput State Hospital   (Turkey)

Author keywords

Glaucoma; Mitomycin C; Octreotide; Tacrolimus; Trabeculectomy

Indexed keywords

FIBROBLAST GROWTH FACTOR; MITOMYCIN C; OCTREOTIDE; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; ENUCLEATION; FIBROBLAST; FILTERING OPERATION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; SCAR FORMATION;

ADMINISTRATION, TOPICAL; ALKYLATING AGENTS; ANIMALS; CICATRIX; CONJUNCTIVAL DISEASES; DISEASE MODELS, ANIMAL; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; FIBROSIS; FILTERING SURGERY; GLAUCOMA; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE COUNT; MITOMYCIN; OCTREOTIDE; OPHTHALMIC SOLUTIONS; POSTOPERATIVE COMPLICATIONS; RABBITS; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84857438734     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2011.635404     Document Type: Article

References (36)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-267.
2. McKinnon SJ, Goldberg LD, Peeples P, Walt JG, Bramley TJ. Current management of glaucoma and the need for complete therapy. Am J Manag Care. 2008;14:S20-S27.
3. Sharaawy T, Bhartiya S. Surgical management of glaucoma: Evolving paradigms. Indian J Ophthalmol. 2011;59 Suppl:S123-S130.
4. Dietlein TS, Hermann MM, Jordan JF. The medical and surgical treatment of glaucoma. Dtsch Arztebl Int. 2009;106:597- 605; quiz 606.
5. Razeghinejad MR, Spaeth GL. A history of the surgical management of glaucoma. Optom Vis Sci. 2011;88:E39-E47.
6. Mendrinos E, Mermoud A, Shaarawy T. Nonpenetrating glaucoma surgery. Surv Ophthalmol. 2008;53:592-630.
7. Coppens G, Maudgal P. Corneal complications of intraoperative Mitomycin C in glaucoma surgery. Bull Soc Belge Ophtalmol. 2010;314:19-23.
8. Jongsareejit B, Tomidokoro A, Mimura T, Tomita G, Shirato S, Araie M. Efficacy and complications after trabeculectomy with mitomycin C in normal-tension glaucoma. Jpn J Ophthalmol. 2005;49:223-227.
9. Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet. 2007;22:328-335.
10. Fort J, Oberti F, Pilette C et al. Antifibrotic and hemodynamic effects of the early and chronic administration of octreotide in two models of liver fibrosis in rats. Hepatology. 1998;28:1525-1531.
11. Xiao YQ, Liu K, Shen JF, Xu GT, Ye W. SB-431542 inhibition of scar formation after filtration surgery and its potential mechanism. Invest Ophthalmol Vis Sci. 2009;50:1698-1706.
12. Vijaya L, Manish P, Ronnie G, Shantha B. Management of complications in glaucoma surgery. Indian J Ophthalmol. 2011;59 Suppl:S131-S140.
13. Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol. 2003;48:314-346.
14. Filippopoulos T, Hanna E, Chen TC, Grosskreutz CL, Jakobiec FA, Pasquale LR. Correlation of filtration bleb morphology with histology. Int Ophthalmol Clin. 2009;49:71-82.
15. Wang XY, Crowston JG, Zoellner H, Healey PR. Interferonalpha and interferon-gamma sensitize human tenon fibroblasts to mitomycin-C. Invest Ophthalmol Vis Sci. 2007;48:3655-3661.
16. Carvalho CS, Viveiros MM, Schellini SA, Candeias JM, Padovani CR. [Fibroblasts from recurrent pterygium and normal Tenon's capsule exposed to tacrolimus (FK-506)]. Arq Bras Oftalmol. 2007;70:235-238.
17. Hofland LJ, van der Burg B, van Eijck CH, Sprij DM, van Koetsveld PM, Lamberts SW. Role of tumor-derived fibroblasts in the growth of primary cultures of human breast-cancer cells: Effects of epidermal growth factor and the somatostatin analogue octreotide. Int J Cancer. 1995;60:93-99.
18. Chang L, Crowston JG, Cordeiro MF, Akbar AN, Khaw PT. The role of the immune system in conjunctival wound healing after glaucoma surgery. Surv Ophthalmol. 2000;45:49-68.
19. Futamura Y, Matsumoto K. Characteristics of peripheral blood monocytes and bone marrow macrophages from rats treated with mitomycin C, 5-fluorouracil or phenylhydrazine. J Toxicol Sci. 1995;20:1-7.
20. Lattuada D, Casnici C, Crotta K et al. Inhibitory effect of pasireotide and octreotide on lymphocyte activation. J Neuroimmunol. 2007;182:153-159.
21. Wiedermann CJ, Reinisch N, Braunsteiner H. Stimulation of monocyte chemotaxis by human growth hormone and its deactivation by somatostatin. Blood. 1993;82:954-960.
22. Horigome A, Hirano T, Oka K. Tacrolimus-induced apoptosis and its prevention by interleukins in mitogenactivated human peripheral-blood mononuclear cells. Immunopharmacology. 1998;39:21-30.
23. Cordeiro MF, Reichel MB, Gay JA, D'Esposita F, Alexander RA, Khaw PT. Transforming growth factor-beta1, -beta2, and -beta3 in vivo: Effects on normal and mitomycin C-modulated conjunctival scarring. Invest Ophthalmol Vis Sci. 1999;40:1975-1982.
24. Giordano A, Romano S, Mallardo M et al. FK506 can activate transforming growth factor-beta signalling in vascular smooth muscle cells and promote proliferation. Cardiovasc Res. 2008;79:519-526.
25. Hasegawa T, Sumiyoshi K, Tsuchihashi H, Ikeda S, Nakao A, Ogawa H. FK506 inhibits the enhancing effects of TGF-beta on wound healing in a rabbit dermal ulcer model. J Dermatol Sci. 2007;47:37-40
26. Erol FS, Kavakli A, Ilhan N, Ozercan IH, Sarsilmaz M. Efects of melatonin and octreotide on peridural fibrosis in an animal model of laminectomy. Turk Neurosurg. 2010;20:50-56.
27. Occleston NL, Daniels JT, Tarnuzzer RW et al. Single exposures to antiproliferatives: long-term effects on ocular fibroblast wound-healing behavior. Invest Ophthalmol Vis Sci. 1997;38:1998-2007.
28. Fealy MJ, Most D, Huie P et al. Association of down-regulation of cytokine activity with rat hind limb allograft survival. Transplantation. 1995;59:1475-1480.
29. Erten C, Karaca B, Kucukzeybek Y et al. Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide. BJU Int. 2009;104:107-114.
30. Dumont FJ. FK506, an immunosuppressant targeting calcineurin function. Curr Med Chem. 2000;7:731-748.
31. Yang LP, Keating GM. Octreotide long-acting release (LAR): A review of its use in the management of acromegaly. Drugs. 2010;70:1745-1769.
32. Sener G, Cetinel S, Erkanli G, Gedik N, Yegen BC. Octreotide ameliorates sepsis-induced pelvic inflammation in female rats by a neutrophil-dependent mechanism. Peptides. 2005;26:493-499.
33. Ohashi Y, Ebihara N, Fujishima H et al. A randomized, placebo- controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. J Ocul Pharmacol Ther. 2010;26:165-174.
34. Akyol N, Demir T, Cobanoglu B, Ulas F. Ciliary body toxicity of cyclosporin A and octreotide acetate in rabbit eyes: A comparison with mitomycin C and 5-fluorouracil. Graefes Arch Clin Exp Ophthalmol. 2003;241:816-822.
35. Demir T, Turgut B, Celiker U, Ozercan I, Ulas F, Akyol N. Effects of octreotide acetate and amniotic membrane on wound healing in experimental glaucoma surgery. Doc Ophthalmol. 2003;107:87-92.
36. Hikita N, Lopez JS, Chan CC, Mochizuki M, Nussenblatt RB, de Smet MD. Use of topical FK506 in a corneal graft rejection model in Lewis rats. Invest Ophthalmol Vis Sci. 1997;38:901-909.